JP2023516381A5 - - Google Patents

Info

Publication number
JP2023516381A5
JP2023516381A5 JP2022552782A JP2022552782A JP2023516381A5 JP 2023516381 A5 JP2023516381 A5 JP 2023516381A5 JP 2022552782 A JP2022552782 A JP 2022552782A JP 2022552782 A JP2022552782 A JP 2022552782A JP 2023516381 A5 JP2023516381 A5 JP 2023516381A5
Authority
JP
Japan
Prior art keywords
cancer
amino acid
alkyl
formula
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022552782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023516381A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2021/002622 external-priority patent/WO2021177721A1/ko
Publication of JP2023516381A publication Critical patent/JP2023516381A/ja
Publication of JP2023516381A5 publication Critical patent/JP2023516381A5/ja
Pending legal-status Critical Current

Links

JP2022552782A 2020-03-03 2021-03-03 Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物 Pending JP2023516381A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20200026381 2020-03-03
KR10-2020-0026381 2020-03-03
PCT/KR2021/002622 WO2021177721A1 (ko) 2020-03-03 2021-03-03 Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물

Publications (2)

Publication Number Publication Date
JP2023516381A JP2023516381A (ja) 2023-04-19
JP2023516381A5 true JP2023516381A5 (cg-RX-API-DMAC10.html) 2024-03-12

Family

ID=77612768

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022552782A Pending JP2023516381A (ja) 2020-03-03 2021-03-03 Kras変異および活性化ronが存在する癌の予防または治療のための医薬組成物

Country Status (6)

Country Link
US (1) US20230099204A1 (cg-RX-API-DMAC10.html)
EP (1) EP4115887A4 (cg-RX-API-DMAC10.html)
JP (1) JP2023516381A (cg-RX-API-DMAC10.html)
KR (1) KR20210111711A (cg-RX-API-DMAC10.html)
CN (1) CN115209900A (cg-RX-API-DMAC10.html)
WO (1) WO2021177721A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
SMT202500028T1 (it) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Terapie combinate
CA3112043A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
US12208099B2 (en) 2018-09-10 2025-01-28 Mirati Therapeutics, Inc. Combination therapies
AU2019338207B2 (en) 2018-09-10 2025-01-02 Mirati Therapeutics, Inc. Combination therapies
US12377101B2 (en) 2018-12-05 2025-08-05 Mirati Therapeutics, Inc. Combination therapies
WO2020146613A1 (en) 2019-01-10 2020-07-16 Mirati Therapeutics, Inc. Kras g12c inhibitors
EP4011885A4 (en) * 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
CN114615981B (zh) 2019-08-29 2024-04-12 米拉蒂治疗股份有限公司 Kras g12d抑制剂
CN114761012B (zh) 2019-09-24 2025-03-21 米拉蒂治疗股份有限公司 组合疗法
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
US12655160B2 (en) 2020-08-04 2026-06-16 Mirati Therapeutics, Inc. KRAS G12D inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
EP4216951B1 (en) 2020-09-22 2026-04-01 Mirati Therapeutics, Inc. Kras g12d inhibitors
EP4262807A4 (en) 2020-12-15 2025-04-23 Mirati Therapeutics, Inc. Azachinazoline pan-KRAS inhibitors
WO2022133038A1 (en) 2020-12-16 2022-06-23 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
KR20230144483A (ko) * 2022-04-06 2023-10-16 웰마커바이오 주식회사 Ron 돌연변이와 관련된 두경부암 예방 또는 치료용 약학 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101390076B1 (ko) 2006-11-08 2014-04-29 브리스톨-마이어스 스큅 컴퍼니 피리디논 화합물
CN102816175B (zh) * 2011-06-09 2015-12-16 上海汇伦生命科技有限公司 一种杂环并吡啶酮类化合物,其中间体、制备方法和用途
US20160206608A1 (en) 2011-08-02 2016-07-21 Pfizer Inc. Crizotinib for use in the treatment of cancer
WO2013155223A1 (en) * 2012-04-10 2013-10-17 The Regents Of The University Of California Compositions and methods for treating cancer
KR101350006B1 (ko) * 2012-09-06 2014-02-13 씨제이제일제당 (주) 피리돈 유도체를 포함하는 단백질 키나제 억제제
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
WO2016018087A1 (ko) * 2014-07-29 2016-02-04 재단법인 아산사회복지재단 Egfr-표적제제에 대한 감수성 예측용 신규한 바이오 마커 및 이의 용도
CN107406492B (zh) * 2014-09-03 2021-12-24 井标记生物 用于预测对蛋白激酶抑制剂的敏感性的生物标记物及其用途
EP3762392B1 (en) * 2018-03-08 2024-05-15 Wellmarker Bio Co., Ltd. Thienopyridine derivatives and pharmaceutical composition comprising same
EP4011885A4 (en) 2019-08-02 2023-01-18 Wellmarker Bio Co., Ltd. CONDENSED CYCLE OXO-PYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THEM
JP2022554042A (ja) * 2019-09-06 2022-12-28 ウェルマーカー・バイオ・カンパニー・リミテッド バイオマーカー型治療用組成物
JP2023513675A (ja) * 2020-02-06 2023-04-03 ウェルマーカー・バイオ・カンパニー・リミテッド Kras変異に関連する癌の予防または治療のための医薬組成物

Similar Documents

Publication Publication Date Title
JP2018511626A5 (cg-RX-API-DMAC10.html)
US20230346790A1 (en) Pharmaceutical composition for prevention or treatment of cancers associated with kras mutation
JP2017528487A5 (cg-RX-API-DMAC10.html)
JP2021011495A5 (cg-RX-API-DMAC10.html)
JP2019529484A5 (cg-RX-API-DMAC10.html)
PE20240239A1 (es) Compuestos heterociclicos
KR20190050794A (ko) 의약 조성물
JP2018524338A5 (cg-RX-API-DMAC10.html)
JP2017514830A5 (cg-RX-API-DMAC10.html)
JP2014526500A5 (cg-RX-API-DMAC10.html)
JP2018520195A5 (cg-RX-API-DMAC10.html)
JP2018515555A5 (cg-RX-API-DMAC10.html)
JP2008535803A5 (cg-RX-API-DMAC10.html)
JP2016538313A5 (cg-RX-API-DMAC10.html)
RU2013154117A (ru) Производные 1-фенил-2-пиридинилалкильных спиртов в качестве ингибиторов фосфодиэстеразы
RU2009125019A (ru) Производные карбоновой кислоты
JP2016512558A5 (cg-RX-API-DMAC10.html)
JP2007510689A5 (cg-RX-API-DMAC10.html)
RU2014123109A (ru) Антибиотические производные 2-оксо-оксазолидин-3, 5-диила
JP2009520685A5 (cg-RX-API-DMAC10.html)
RU2015101102A (ru) Гетероароматическое метильное производное циклического амина
RU2010150786A (ru) Пирролопиридины как ингибиторы киназы
JP2003528917A5 (cg-RX-API-DMAC10.html)
RU2011139321A (ru) Модулирующие jak киназу хиназолиновые производные и способы их применения
JP2012087129A5 (cg-RX-API-DMAC10.html)